J.ReillyP
BPC-157 may not be appropriate when: Imaging or specialist review has not yet been completed for a suspected structural injury There are acute red flag features (severe weakness, fever, rapid unexplained swelling, neurological changes, unexplained weight loss) The patient has active cancer or a history of certain cancers where angiogenic peptides require careful risk assessment The goal is rapid results without addressing underlying load, rehabilitation, or lifestyle drivers A peptide should not be used to delay evaluation that is clearly warranted
(TCPA), and all regulations implementing the TCPA, including without limitation 47 C.F.R
For a blend like DSIP, Selank, and Semax, this is often done five to seven times a week to help your body make the most of the peptides and achieve consistent results
Those numbers buy you a licensed medical provider, a 503A compounding pharmacy supply chain, individualized dosing, in-person injection training, and follow-up at the clinic
